autoimmune diseases

First healthy volunteers dosed in Phase 1 trial of LPX-TI641

A Phase 1 clinical trial evaluating LPX-TI641, Lapix Therapeutics‘ experimental therapy for multiple sclerosis (MS) and other autoimmune diseases, has dosed its first participants. The first-in-human trial (NCT05853835) of healthy adult volunteers follows the recent clearance of an investigational new drug application by the U.S. Food…

CerraCap invests in Predicta Med’s autoimmune disease platform

The startup company Predicta Med has received an investment from CerraCap Ventures to advance its leading platform focused on early diagnosis and treatment of multiple sclerosis (MS) and other immune-related diseases. The Israel-based startup has created the world’s first platform designed to use medical information to determine…

1st RRMS Patient Dosed in Phase 1/2 Trial of Immunotherapy IMCY-0141

A Phase 1/2 clinical trial evaluating Imcyseā€™s experimental therapy IMCY-0141 in people with relapsing-remitting multiple sclerosisĀ (RRMS) has dosed its first patient. The trial, called IMCY-MS-001, is expected to enroll nearly 150 adults with RRMS;Ā sites were not disclosed in a release by the Belgium-based company. Interim results may be available…

COVID-19 Vaccine Trial Testing Extra Dose in MS, Other Diseases

A new clinical trial launched by the National Institutes of Health (NIH) is evaluating the impact of an extra dose of an approved or authorized COVID-19 vaccine in people withĀ multiple sclerosis (MS) and other autoimmune diseasesĀ who did not properly respond to an original vaccine regimen. Approximately 600 people will…

Collaboration Explores Therapies for Autoimmune Diseases

Cytocom has joined forces with La Jolla Institute for Immunology (LJI) to discover and develop new immune-modulating therapies targeting toll-like receptors (TLRs) for autoimmune diseases such as multiple sclerosisĀ (MS), cancer, and infectious and chronic inflammatory conditions. TLRs are an important family of protein receptors found at the surface…

Sugar Molecules in Yeast Cells Prevent Inflammation in Mouse Model

A component of yeast cell walls ā€” called MGCP ā€” prevented disease in a mouse model of multiple sclerosis (MS) by activating anti-inflammatory immune T-cells while suppressing inflammatory T-cells, a study showed. This work also supporting the microbiomeā€™s role in affecting inflammation in autoimmune diseases like MS. “We have…

NMSS Partnership Targets Autoimmune Disease Research

The National Multiple Sclerosis Society has joined forces with the diabetes-focused JDRF and the Lupus Research Alliance to fund research looking at common underlying mechanisms of autoimmune disease. Called “Decoding Immune-Mediated Diseases ā€“ Novel Approaches for Therapeutic Insights,” the new joint grant program is meant to stimulate…

TH17-suppressing Pregnancy Proteins May Be MS Therapeutic Target

Proteins called PSGs suppress the pro-inflammatory activity of immune Th17 cells during pregnancy, potentially playing a protective role against complications and miscarriage, a study finds.Ā  The impaired regulation of Th17 is associated with pregnancy complications, like preeclampsia and preterm delivery ā€” and also with the development…

European Patent Given to IMP761, Antibody Aiming to Treat MS

The European Patent Office granted a patent for IMP761, Immutep‘s experimental antibody to be used in treating inflammatory and autoimmune conditions, including multiple sclerosis (MS). IMP761 targets a receptor found on the surface of immune system T-cellsĀ calledĀ lymphocyte-activation gene 3,…